Cybrexa Therapeutics: Funding, Investors & Team (Oct 2026)
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.
Cybrexa Therapeutics has raised $25.0M across 1 funding round on record, the most recent a Series B of $25.0M announced in Mar 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cybrexa Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2021.
Cybrexa Therapeutics Funding Rounds
Cybrexa Therapeutics Founders and Leadership Team
Contact details for the Cybrexa Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Cybrexa Therapeutics Funding Compared to Other Biotechnology Startups
Cybrexa Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cybrexa Therapeutics in Biotechnology and New Haven
Companies Similar to Cybrexa Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Cybrexa Therapeutics Funding FAQs
What does Cybrexa Therapeutics do?
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.
How much funding has Cybrexa Therapeutics raised?
Cybrexa Therapeutics has raised $25.0M across 1 round on record. The most recent is a Series B of $25.0M announced in Mar 2021.
When did Cybrexa Therapeutics last raise funding?
Cybrexa Therapeutics' most recent funding round on record is a Series B of $25.0M, announced in Mar 2021.
Who is the CEO of Cybrexa Therapeutics?
Per Hellsund is listed as CEO at Cybrexa Therapeutics.
Where is Cybrexa Therapeutics headquartered?
Cybrexa Therapeutics is based in New Haven, Connecticut, United States.
How many employees does Cybrexa Therapeutics have?
Cybrexa Therapeutics is in the 11-50 employee band.
How does Cybrexa Therapeutics' funding compare to other Biotechnology startups?
Cybrexa Therapeutics' latest round of $25.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Cybrexa Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cybrexa Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.